The role of alternative splicing in lung cancer.
Alternative splicing
Diagnosis
Lung cancer
Prognosis
Treatment
Journal
Cancer chemotherapy and pharmacology
ISSN: 1432-0843
Titre abrégé: Cancer Chemother Pharmacol
Pays: Germany
ID NLM: 7806519
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
received:
09
02
2023
accepted:
12
06
2023
medline:
10
7
2023
pubmed:
19
6
2023
entrez:
19
6
2023
Statut:
ppublish
Résumé
Aberrant alternative splicing (AS) events are frequently observed in lung cancer, which can be attributed to aberrant gene AS, alterations in splicing regulatory factors, or changes in splicing regulatory mechanisms. Consequently, the dysregulation of alternative RNA splicing is the fundamental cause of lung cancer. In this review, we have summarized the pivotal role of AS in the development, progression, invasion, metastasis, angiogenesis, and drug resistance of lung cancer. Ultimately, this review emphasizes the potential of AS as biomarkers in lung cancer prognosis and diagnosis, and introduces some applications of AS isoform in the treatment of lung cancer. The comprehension of the AS may provide a glimmer of hope for the eradication of lung cancer.
Identifiants
pubmed: 37335335
doi: 10.1007/s00280-023-04553-4
pii: 10.1007/s00280-023-04553-4
doi:
Substances chimiques
RNA Splicing Factors
0
Biomarkers
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
83-95Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Siegel RL, Miller KD, Fuchs HE, Jemal A (2022) Cancer statistics, 2022. CA Cancer J Clin 72:7–33. https://doi.org/10.3322/caac.21708
doi: 10.3322/caac.21708
pubmed: 35020204
Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS (2021) Lung cancer. Lancet 398:535–554. https://doi.org/10.1016/s0140-6736(21)00312-3
doi: 10.1016/s0140-6736(21)00312-3
pubmed: 34273294
Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, Chirieac LR, Dacic S, Duhig E, Flieder DB, Geisinger K, Hirsch FR, Ishikawa Y, Kerr KM, Noguchi M, Pelosi G, Powell CA, Tsao MS, Wistuba I (2015) The 2015 world health organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol 10:1243–1260. https://doi.org/10.1097/jto.0000000000000630
doi: 10.1097/jto.0000000000000630
pubmed: 26291008
Herbst RS, Morgensztern D, Boshoff C (2018) The biology and management of non-small cell lung cancer. Nature 553:446–454. https://doi.org/10.1038/nature25183
doi: 10.1038/nature25183
pubmed: 29364287
Chow LT, Gelinas RE, Broker TR, Roberts RJ (1977) An amazing sequence arrangement at the 5′ ends of adenovirus 2 messenger RNA. Cell 12:1–8. https://doi.org/10.1016/0092-8674(77)90180-5
doi: 10.1016/0092-8674(77)90180-5
pubmed: 902310
Wahl MC, Lührmann R (2015) SnapShot: spliceosome dynamics I. Cell 161:1474-e1471. https://doi.org/10.1016/j.cell.2015.05.050
doi: 10.1016/j.cell.2015.05.050
pubmed: 26046445
Hegele A, Kamburov A, Grossmann A, Sourlis C, Wowro S, Weimann M, Will CL, Pena V, Lührmann R, Stelzl U (2012) Dynamic protein-protein interaction wiring of the human spliceosome. Mol Cell 45:567–580. https://doi.org/10.1016/j.molcel.2011.12.034
doi: 10.1016/j.molcel.2011.12.034
pubmed: 22365833
Rossbach O, Hung LH, Schreiner S, Grishina I, Heiner M, Hui J, Bindereif A (2009) Auto- and cross-regulation of the hnRNP L proteins by alternative splicing. Mol Cell Biol 29:1442–1451. https://doi.org/10.1128/mcb.01689-08
doi: 10.1128/mcb.01689-08
pubmed: 19124611
pmcid: 2648227
Cáceres JF, Kornblihtt AR (2002) Alternative splicing: multiple control mechanisms and involvement in human disease. Trends Genet 18:186–193. https://doi.org/10.1016/s0168-9525(01)02626-9
doi: 10.1016/s0168-9525(01)02626-9
pubmed: 11932019
Llorian M, Schwartz S, Clark TA, Hollander D, Tan LY, Spellman R, Gordon A, Schweitzer AC, de la Grange P, Ast G, Smith CW (2010) Position-dependent alternative splicing activity revealed by global profiling of alternative splicing events regulated by PTB. Nat Struct Mol Biol 17:1114–1123. https://doi.org/10.1038/nsmb.1881
doi: 10.1038/nsmb.1881
pubmed: 20711188
pmcid: 2933513
Ladd AN (2013) CUG-BP, Elav-like family (CELF)-mediated alternative splicing regulation in the brain during health and disease. Mol Cell Neurosci 56:456–464. https://doi.org/10.1016/j.mcn.2012.12.003
doi: 10.1016/j.mcn.2012.12.003
pubmed: 23247071
Eilertsen IA, Sveen A, Strømme JM, Skotheim RI, Nesbakken A, Lothe RA (2019) Alternative splicing expands the prognostic impact of KRAS in microsatellite stable primary colorectal cancer. Int J Cancer 144:841–847. https://doi.org/10.1002/ijc.31809
doi: 10.1002/ijc.31809
pubmed: 30121958
Matlin AJ, Clark F, Smith CW (2005) Understanding alternative splicing: towards a cellular code. Nat Rev Mol Cell Biol 6:386–398. https://doi.org/10.1038/nrm1645
doi: 10.1038/nrm1645
pubmed: 15956978
Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ (2008) Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet 40:1413–1415. https://doi.org/10.1038/ng.259
doi: 10.1038/ng.259
pubmed: 18978789
Keren H, Lev-Maor G, Ast G (2010) Alternative splicing and evolution: diversification, exon definition and function. Nat Rev Genet 11:345–355. https://doi.org/10.1038/nrg2776
doi: 10.1038/nrg2776
pubmed: 20376054
Sugnet CW, Kent WJ, Ares M Jr, Haussler D (2004) Transcriptome and genome conservation of alternative splicing events in humans and mice. Pac Symp Biocomput. https://doi.org/10.1142/9789812704856_0007
doi: 10.1142/9789812704856_0007
pubmed: 14992493
Climente-González H, Porta-Pardo E, Godzik A, Eyras E (2017) The functional impact of alternative splicing in cancer. Cell Rep 20:2215–2226. https://doi.org/10.1016/j.celrep.2017.08.012
doi: 10.1016/j.celrep.2017.08.012
pubmed: 28854369
Coomer AO, Black F, Greystoke A, Munkley J, Elliott DJ (2019) Alternative splicing in lung cancer. Biochim Biophys Acta Gene Regul Mech 1862:194388. https://doi.org/10.1016/j.bbagrm.2019.05.006
doi: 10.1016/j.bbagrm.2019.05.006
pubmed: 31152916
Pio R, Montuenga LM (2009) Alternative splicing in lung cancer. J Thorac Oncol 4:674–678. https://doi.org/10.1097/JTO.0b013e3181a520dc
doi: 10.1097/JTO.0b013e3181a520dc
pubmed: 19461400
Mizera-Nyczak E, Dyszkiewicz W, Heider KH, Zeromski J (2001) Isoform expression of CD44 adhesion molecules, Bcl-2, p53 and Ki-67 proteins in lung cancer. Tumour Biol 22:45–53. https://doi.org/10.1159/000030154
doi: 10.1159/000030154
pubmed: 11054026
Yuan Y, Sun L, Wang X, Chen J, Jia M, Zou Y, Sa H, Cai Y, Xu Y, Sun C, Guo Y, Li H, Ma K (2019) Identification of a new GLDC gene alternative splicing variant and its protumorigenic roles in lung cancer. Future Oncol 15:4127–4139. https://doi.org/10.2217/fon-2019-0403
doi: 10.2217/fon-2019-0403
pubmed: 31773974
Kure S, Kato K, Dinopoulos A, Gail C, DeGrauw TJ, Christodoulou J, Bzduch V, Kalmanchey R, Fekete G, Trojovsky A, Plecko B, Breningstall G, Tohyama J, Aoki Y, Matsubara Y (2006) Comprehensive mutation analysis of GLDC, AMT, and GCSH in nonketotic hyperglycinemia. Hum Mutat 27:343–352. https://doi.org/10.1002/humu.20293
doi: 10.1002/humu.20293
pubmed: 16450403
Kanno E, Kawasaki O, Takahashi K, Takano K, Endo T (2018) DA-Raf, a dominant-negative antagonist of the Ras-ERK pathway, is a putative tumor suppressor. Exp Cell Res 362:111–120. https://doi.org/10.1016/j.yexcr.2017.11.008
doi: 10.1016/j.yexcr.2017.11.008
pubmed: 29129563
Shimojo M, Shudo Y, Ikeda M, Kobashi T, Ito S (2013) The small cell lung cancer-specific isoform of RE1-silencing transcription factor (REST) is regulated by neural-specific Ser/Arg repeat-related protein of 100 kDa (nSR100). Mol Cancer Res 11:1258–1268. https://doi.org/10.1158/1541-7786.Mcr-13-0269
doi: 10.1158/1541-7786.Mcr-13-0269
pubmed: 23928058
Liu Y, Dong QZ, Zhao Y, Dong XJ, Miao Y, Dai SD, Yang ZQ, Zhang D, Wang Y, Li QC, Zhao C, Wang EH (2009) P120-catenin isoforms 1A and 3A differently affect invasion and proliferation of lung cancer cells. Exp Cell Res 315:890–898. https://doi.org/10.1016/j.yexcr.2008.12.016
doi: 10.1016/j.yexcr.2008.12.016
pubmed: 19150613
Fan YC, Min L, Chen H, Liu YL (2015) Alternative splicing isoform of T cell factor 4K suppresses the proliferation and metastasis of non-small cell lung cancer cells. Genet Mol Res 14:14009–14018. https://doi.org/10.4238/2015.October.29.20
doi: 10.4238/2015.October.29.20
pubmed: 26535715
Wang J, Liu T, Wang M, Lv W, Wang Y, Jia Y, Zhang R, Liu L (2020) SRSF1-dependent alternative splicing attenuates BIN1 expression in non-small cell lung cancer. J Cell Biochem 121:946–953. https://doi.org/10.1002/jcb.29366
doi: 10.1002/jcb.29366
pubmed: 31478261
Karlsson MC, Gonzalez SF, Welin J, Fuxe J (2017) Epithelial-mesenchymal transition in cancer metastasis through the lymphatic system. Mol Oncol 11:781–791. https://doi.org/10.1002/1878-0261.12092
doi: 10.1002/1878-0261.12092
pubmed: 28590032
pmcid: 5496496
Iwano M (2010) EMT and TGF-beta in renal fibrosis. Front Biosci (Schol Ed) 2:229–238. https://doi.org/10.2741/s60
doi: 10.2741/s60
pubmed: 20036943
Zhao M, Mishra L, Deng CX (2018) The role of TGF-β/SMAD4 signaling in cancer. Int J Biol Sci 14:111–123. https://doi.org/10.7150/ijbs.23230
doi: 10.7150/ijbs.23230
pubmed: 29483830
pmcid: 5821033
Chen CY, Jan CI, Pi WC, Wang WL, Yang PC, Wang TH, Karni R, Wang TC (2016) Heterogeneous nuclear ribonucleoproteins A1 and A2 modulate expression of Tid1 isoforms and EGFR signaling in non-small cell lung cancer. Oncotarget 7:16760–16772. https://doi.org/10.18632/oncotarget.7606
doi: 10.18632/oncotarget.7606
pubmed: 26919236
pmcid: 4941349
Wan R, Xu X, Ma L, Chen Y, Tang L, Feng J (2020) Novel alternatively spliced variants of smad4 expressed in TGF-β-induced EMT regulating proliferation and migration of A549 cells. Onco Targets Ther 13:2203–2213. https://doi.org/10.2147/ott.S247015
doi: 10.2147/ott.S247015
pubmed: 32210586
pmcid: 7073448
Li S, Shen L, Huang L, Lei S, Cai X, Breitzig M, Zhang B, Yang A, Ji W, Huang M, Zheng Q, Sun H, Wang F (2019) PTBP1 enhances exon11a skipping in Mena pre-mRNA to promote migration and invasion in lung carcinoma cells. Biochim Biophys Acta Gene Regul Mech 1862:858–869. https://doi.org/10.1016/j.bbagrm.2019.04.006
doi: 10.1016/j.bbagrm.2019.04.006
pubmed: 31075540
Mao S, Li Y, Lu Z, Che Y, Huang J, Lei Y, Wang Y, Liu C, Wang X, Zheng S, Sun N, He J (2019) PHD finger protein 5A promoted lung adenocarcinoma progression via alternative splicing. Cancer Med 8:2429–2441. https://doi.org/10.1002/cam4.2115
doi: 10.1002/cam4.2115
pubmed: 30932358
pmcid: 6536992
Romero-Garcia S, Prado-Garcia H, Lopez-Gonzalez JS (2014) Transcriptional analysis of hnRNPA0, A1, A2, B1, and A3 in lung cancer cell lines in response to acidosis, hypoxia, and serum deprivation conditions. Exp Lung Res 40:12–21. https://doi.org/10.3109/01902148.2013.856049
doi: 10.3109/01902148.2013.856049
pubmed: 24246049
Melincovici CS, Boşca AB, Şuşman S, Mărginean M, Mihu C, Istrate M, Moldovan IM, Roman AL, Mihu CM (2018) Vascular endothelial growth factor (VEGF)—key factor in normal and pathological angiogenesis. Rom J Morphol Embryol 59:455–467
pubmed: 30173249
Mei H, Wang Y, Fan J, Lin Z (2016) Alternative splicing of S6K1 promotes non-small cell lung cancer survival. Tumour Biol 37:13369–13376. https://doi.org/10.1007/s13277-016-5253-1
doi: 10.1007/s13277-016-5253-1
pubmed: 27460085
Berndorff D, Borkowski S, Moosmayer D, Viti F, Müller-Tiemann B, Sieger S, Friebe M, Hilger CS, Zardi L, Neri D, Dinkelborg LM (2006) Imaging of tumor angiogenesis using 99mTc-labeled human recombinant anti-ED-B fibronectin antibody fragments. J Nucl Med 47:1707–1716
pubmed: 17015908
Das S, Anczuków O, Akerman M, Krainer AR (2012) Oncogenic splicing factor SRSF1 is a critical transcriptional target of MYC. Cell Rep 1:110–117. https://doi.org/10.1016/j.celrep.2011.12.001
doi: 10.1016/j.celrep.2011.12.001
pubmed: 22545246
pmcid: 3334311
Urbanski LM, Leclair N, Anczuków O (2018) Alternative-splicing defects in cancer: splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics. WIREs RNA 9:e1476. https://doi.org/10.1002/wrna.1476
doi: 10.1002/wrna.1476
pubmed: 29693319
Maraver A, Fernández-Marcos PJ, Herranz D, Muñoz-Martin M, Gomez-Lopez G, Cañamero M, Mulero F, Megías D, Sanchez-Carbayo M, Shen J, Sanchez-Cespedes M, Palomero T, Ferrando A, Serrano M (2012) Therapeutic effect of γ-secretase inhibition in KrasG12V-driven non-small cell lung carcinoma by derepression of DUSP1 and inhibition of ERK. Cancer Cell 22:222–234. https://doi.org/10.1016/j.ccr.2012.06.014
doi: 10.1016/j.ccr.2012.06.014
pubmed: 22897852
Zong FY, Fu X, Wei WJ, Luo YG, Heiner M, Cao LJ, Fang Z, Fang R, Lu D, Ji H, Hui J (2014) The RNA-binding protein QKI suppresses cancer-associated aberrant splicing. PLoS Genetics 10:e1004289. https://doi.org/10.1371/journal.pgen.1004289
doi: 10.1371/journal.pgen.1004289
pubmed: 24722255
pmcid: 3983035
Bechara EG, Sebestyén E, Bernardis I, Eyras E, Valcárcel J (2013) RBM5, 6, and 10 differentially regulate NUMB alternative splicing to control cancer cell proliferation. Mol Cell 52:720–733. https://doi.org/10.1016/j.molcel.2013.11.010
doi: 10.1016/j.molcel.2013.11.010
pubmed: 24332178
Hernández J, Bechara E, Schlesinger D, Delgado J, Serrano L, Valcárcel J (2016) Tumor suppressor properties of the splicing regulatory factor RBM10. RNA Biol 13:466–472. https://doi.org/10.1080/15476286.2016.1144004
doi: 10.1080/15476286.2016.1144004
pubmed: 26853560
pmcid: 4841610
Misquitta-Ali CM, Cheng E, O’Hanlon D, Liu N, McGlade CJ, Tsao MS, Blencowe BJ (2011) Global profiling and molecular characterization of alternative splicing events misregulated in lung cancer. Mol Cell Biol 31:138–150. https://doi.org/10.1128/mcb.00709-10
doi: 10.1128/mcb.00709-10
pubmed: 21041478
Liu Y, Wu BQ, Zhong HH, Tian XX, Fang WG (2012) Quantification of alternative splicing variants of human telomerase reverse transcriptase and correlations with telomerase activity in lung cancer. PLoS One 7:e38868. https://doi.org/10.1371/journal.pone.0038868
doi: 10.1371/journal.pone.0038868
pubmed: 22723897
pmcid: 3377688
Ohwada A, Takahashi H, Nagaoka I, Kira S (1994) Biliary glycoprotein mRNA expression is increased in primary lung cancer, especially in squamous cell carcinoma. Am J Respir Cell Mol Biol 11:214–220. https://doi.org/10.1165/ajrcmb.11.2.8049082
doi: 10.1165/ajrcmb.11.2.8049082
pubmed: 8049082
Ludlow AT, Wong MS, Robin JD, Batten K, Yuan L, Lai TP, Dahlson N, Zhang L, Mender I, Tedone E, Sayed ME, Wright WE, Shay JW (2018) NOVA1 regulates hTERT splicing and cell growth in non-small cell lung cancer. Nat Commun 9:3112. https://doi.org/10.1038/s41467-018-05582-x
doi: 10.1038/s41467-018-05582-x
pubmed: 30082712
pmcid: 6079032
Sayed ME, Yuan L, Robin JD, Tedone E, Batten K, Dahlson N, Wright WE, Shay JW, Ludlow AT (2019) NOVA1 directs PTBP1 to hTERT pre-mRNA and promotes telomerase activity in cancer cells. Oncogene 38:2937–2952. https://doi.org/10.1038/s41388-018-0639-8
doi: 10.1038/s41388-018-0639-8
pubmed: 30568224
Fujiwara M, Kamma H, Wu W, Hamasaki M, Kaneko S, Horiguchi H, Matsui-Horiguchi M, Satoh H (2004) Expression and alternative splicing pattern of human telomerase reverse transcriptase in human lung cancer cells. Int J Oncol 24:925–930
pubmed: 15010831
Kang HJ, Choi YS, Hong SB, Kim KW, Woo RS, Won SJ, Kim EJ, Jeon HK, Jo SY, Kim TK, Bachoo R, Reynolds IJ, Gwag BJ, Lee HW (2004) Ectopic expression of the catalytic subunit of telomerase protects against brain injury resulting from ischemia and NMDA-induced neurotoxicity. J Neurosci 24:1280–1287. https://doi.org/10.1523/jneurosci.4082-03.2004
doi: 10.1523/jneurosci.4082-03.2004
pubmed: 14960598
pmcid: 6730349
Maida Y, Yasukawa M, Furuuchi M, Lassmann T, Possemato R, Okamoto N, Kasim V, Hayashizaki Y, Hahn WC, Masutomi K (2009) An RNA-dependent RNA polymerase formed by TERT and the RMRP RNA. Nature 461:230–235. https://doi.org/10.1038/nature08283
doi: 10.1038/nature08283
pubmed: 19701182
pmcid: 2755635
Masutomi K, Possemato R, Wong JM, Currier JL, Tothova Z, Manola JB, Ganesan S, Lansdorp PM, Collins K, Hahn WC (2005) The telomerase reverse transcriptase regulates chromatin state and DNA damage responses. Proc Natl Acad Sci USA 102:8222–8227. https://doi.org/10.1073/pnas.0503095102
doi: 10.1073/pnas.0503095102
pubmed: 15928077
pmcid: 1149439
Bria E, Di Modugno F, Sperduti I, Iapicca P, Visca P, Alessandrini G, Antoniani B, Pilotto S, Ludovini V, Vannucci J, Bellezza G, Sidoni A, Tortora G, Radisky DC, Crinò L, Cognetti F, Facciolo F, Mottolese M, Milella M, Nisticò P (2014) Prognostic impact of alternative splicing-derived hMENA isoforms in resected, node-negative, non-small-cell lung cancer. Oncotarget 5:11054–11063. https://doi.org/10.18632/oncotarget.2609
doi: 10.18632/oncotarget.2609
pubmed: 25373410
pmcid: 4294370
Li S, Yang E, Shen L, Niu D, Breitzig M, Tan LC, Wu X, Huang M, Sun H, Wang F (2018) The novel truncated isoform of human manganese superoxide dismutase has a differential role in promoting metastasis of lung cancer cells. Cell Biol Int 42:1030–1040. https://doi.org/10.1002/cbin.10972
doi: 10.1002/cbin.10972
pubmed: 29660197
Chang HL, Lin JC (2019) SRSF1 and RBM4 differentially modulate the oncogenic effect of HIF-1α in lung cancer cells through alternative splicing mechanism. Biochim Biophys Acta Mol Cell Res 1866:118550. https://doi.org/10.1016/j.bbamcr.2019.118550
doi: 10.1016/j.bbamcr.2019.118550
pubmed: 31491447
Li S, Ma J, Si Y, Cheng S, Hu M, Zhi X, Li B, Yu H, Jiang WG (2019) Differential expression and functions of Ehm2 transcript variants in lung adenocarcinoma. Int J Oncol 54:1747–1758. https://doi.org/10.3892/ijo.2019.4732
doi: 10.3892/ijo.2019.4732
pubmed: 30816447
Qu S, Jiao Z, Lu G, Yao B, Wang T, Rong W, Xu J, Fan T, Sun X, Yang R, Wang J, Yao Y, Xu G, Yan X, Wang T, Liang H, Zen K (2021) PD-L1 lncRNA splice isoform promotes lung adenocarcinoma progression via enhancing c-Myc activity. Genome Biol 22:104. https://doi.org/10.1186/s13059-021-02331-0
doi: 10.1186/s13059-021-02331-0
pubmed: 33849634
pmcid: 8042710
Wang JZ, Fu X, Fang Z, Liu H, Zong FY, Zhu H, Yu YF, Zhang XY, Wang SF, Huang Y, Hui J (2021) QKI-5 regulates the alternative splicing of cytoskeletal gene ADD3 in lung cancer. J Mol Cell Biol 13:347–360. https://doi.org/10.1093/jmcb/mjaa063
doi: 10.1093/jmcb/mjaa063
pubmed: 33196842
Oshika Y, Nakamura M, Tokunaga T, Ohnishi Y, Abe Y, Tsuchida T, Tomii Y, Kijima H, Yamazaki H, Ozeki Y, Tamaoki N, Ueyama Y (2000) Ribozyme approach to downregulate vascular endothelial growth factor (VEGF) 189 expression in non-small cell lung cancer (NSCLC). Eur J Cancer 36:2390–2396. https://doi.org/10.1016/s0959-8049(00)00343-9
doi: 10.1016/s0959-8049(00)00343-9
pubmed: 11094315
Santimaria M, Moscatelli G, Viale GL, Giovannoni L, Neri G, Viti F, Leprini A, Borsi L, Castellani P, Zardi L, Neri D, Riva P (2003) Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin Cancer Res 9:571–579
pubmed: 12576420
Castellani P, Viale G, Dorcaratto A, Nicolo G, Kaczmarek J, Querze G, Zardi L (1994) The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis. Int J Cancer 59:612–618. https://doi.org/10.1002/ijc.2910590507
doi: 10.1002/ijc.2910590507
pubmed: 7525495
Tarli L, Balza E, Viti F, Borsi L, Castellani P, Berndorff D, Dinkelborg L, Neri D, Zardi L (1999) A high-affinity human antibody that targets tumoral blood vessels. Blood 94:192–198
doi: 10.1182/blood.V94.1.192.413k22_192_198
pubmed: 10381513
Cheng KT (2004) Molecular imaging and contrast agent database (MICAD). National Center for Biotechnology Information (US), Bethesda
Eisenreich A, Zakrzewicz A, Huber K, Thierbach H, Pepke W, Goldin-Lang P, Schultheiss HP, Pries A, Rauch U (2013) Regulation of pro-angiogenic tissue factor expression in hypoxia-induced human lung cancer cells. Oncol Rep 30:462–470. https://doi.org/10.3892/or.2013.2413
doi: 10.3892/or.2013.2413
pubmed: 23604472
Shultz JC, Goehe RW, Murudkar CS, Wijesinghe DS, Mayton EK, Massiello A, Hawkins AJ, Mukerjee P, Pinkerman RL, Park MA, Chalfant CE (2011) SRSF1 regulates the alternative splicing of caspase 9 via a novel intronic splicing enhancer affecting the chemotherapeutic sensitivity of non-small cell lung cancer cells. Mol Cancer Res 9:889–900. https://doi.org/10.1158/1541-7786.Mcr-11-0061
doi: 10.1158/1541-7786.Mcr-11-0061
pubmed: 21622622
pmcid: 3140550
Zheng M, Niu Y, Bu J, Liang S, Zhang Z, Liu J, Guo L, Zhang Z, Wang Q (2021) ESRP1 regulates alternative splicing of CARM1 to sensitize small cell lung cancer cells to chemotherapy by inhibiting TGF-β/Smad signaling. Aging 13:3554–3572. https://doi.org/10.18632/aging.202295
doi: 10.18632/aging.202295
pubmed: 33495408
pmcid: 7906186
Santarpia M, Daffinà MG, Karachaliou N, González-Cao M, Lazzari C, Altavilla G, Rosell R (2016) Targeted drugs in small-cell lung cancer. Transl Lung Cancer Res 5:51–70. https://doi.org/10.3978/j.issn.2218-6751.2016.01.12
doi: 10.3978/j.issn.2218-6751.2016.01.12
pubmed: 26958493
pmcid: 4758978
Mamdani H, Induru R, Jalal SI (2015) Novel therapies in small cell lung cancer. Transl Lung Cancer Res 4:533–544. https://doi.org/10.3978/j.issn.2218-6751.2015.07.20
doi: 10.3978/j.issn.2218-6751.2015.07.20
pubmed: 26629422
pmcid: 4630526
Lehman JM, Gwin ME, Massion PP (2017) Immunotherapy and targeted therapy for small cell lung cancer: there is hope. Curr Oncol Rep 19:49. https://doi.org/10.1007/s11912-017-0609-2
doi: 10.1007/s11912-017-0609-2
pubmed: 28643173
Brinton LT, Sloane HS, Kester M, Kelly KA (2015) Formation and role of exosomes in cancer. Cell Mol Life Sci 72:659–671. https://doi.org/10.1007/s00018-014-1764-3
doi: 10.1007/s00018-014-1764-3
pubmed: 25336151
Mamdani H, Ahmed S, Armstrong S, Mok T, Jalal SI (2017) Blood-based tumor biomarkers in lung cancer for detection and treatment. Transl Lung Cancer Res 6:648–660. https://doi.org/10.21037/tlcr.2017.09.03
doi: 10.21037/tlcr.2017.09.03
pubmed: 29218268
pmcid: 5709129
Vander Borght A, Duysinx M, Broers JLV, Ummelen M, Falkenberg FW, Hahnel C, van der Zeijst BAM (2018) The 180 splice variant of NCAM-containing exon 18-is specifically expressed in small cell lung cancer cells. Transl Lung Cancer Res 7:376–388. https://doi.org/10.21037/tlcr.2018.03.03
doi: 10.21037/tlcr.2018.03.03
pubmed: 30050775
pmcid: 6037973
DiFeo A, Feld L, Rodriguez E, Wang C, Beer DG, Martignetti JA, Narla G (2008) A functional role for KLF6-SV1 in lung adenocarcinoma prognosis and chemotherapy response. Can Res 68:965–970. https://doi.org/10.1158/0008-5472.Can-07-2604
doi: 10.1158/0008-5472.Can-07-2604
Brandt AC, McNally L, Lorimer EL, Unger B, Koehn OJ, Suazo KF, Rein L, Szabo A, Tsaih SW, Distefano MD, Flister MJ, Rigo F, McNally MT, Williams CL (2020) Splice switching an oncogenic ratio of SmgGDS isoforms as a strategy to diminish malignancy. Proc Natl Acad Sci USA 117:3627–3636. https://doi.org/10.1073/pnas.1914153117
doi: 10.1073/pnas.1914153117
pubmed: 32019878
pmcid: 7035473
Sato S, Noguchi Y, Ohara N, Uenaka A, Shimono M, Nakagawa K, Koizumi F, Ishida T, Yoshino T, Shiratori Y, Nakayama E (2007) Identification of XAGE-1 isoforms: predominant expression of XAGE-1b in testis and tumors. Cancer Immun 7:5
pubmed: 17335148
pmcid: 2935747
Sheng J, Zhao Q, Zhao J, Zhang W, Sun Y, Qin P, Lv Y, Bai L, Yang Q, Chen L, Qi Y, Zhang G, Zhang L, Gu C, Deng X, Liu H, Meng S, Gu H, Liu Q, Coulson JM, Li X, Sun B, Wang Y (2018) SRSF1 modulates PTPMT1 alternative splicing to regulate lung cancer cell radioresistance. EBioMedicine 38:113–126. https://doi.org/10.1016/j.ebiom.2018.11.007
doi: 10.1016/j.ebiom.2018.11.007
pubmed: 30429088
pmcid: 6306353
Albert BJ, McPherson PA, O’Brien K, Czaicki NL, Destefino V, Osman S, Li M, Day BW, Grabowski PJ, Moore MJ, Vogt A, Koide K (2009) Meayamycin inhibits pre-messenger RNA splicing and exhibits picomolar activity against multidrug-resistant cells. Mol Cancer Ther 8:2308–2318. https://doi.org/10.1158/1535-7163.Mct-09-0051
doi: 10.1158/1535-7163.Mct-09-0051
pubmed: 19671752
pmcid: 2762647
Zhu Z, Chen D, Zhang W, Zhao J, Zhi L, Huang F, Ji H, Zhang J, Liu H, Zou L, Wang Y (2018) Modulation of alternative splicing induced by paclitaxel in human lung cancer. Cell Death Dis 9:491. https://doi.org/10.1038/s41419-018-0539-4
doi: 10.1038/s41419-018-0539-4
pubmed: 29706628
pmcid: 5924756
Voss OH, Arango D, Tossey JC, Villalona Calero MA, Doseff AI (2021) Splicing reprogramming of TRAIL/DISC-components sensitizes lung cancer cells to TRAIL-mediated apoptosis. Cell Death Dis 12:287. https://doi.org/10.1038/s41419-021-03567-1
doi: 10.1038/s41419-021-03567-1
pubmed: 33731677
pmcid: 7969956
Arriagada R, Auperin A, Burdett S, Higgins JP, Johnson DH, Le Chevalier T, Le Pechoux C, Parmar MK, Pignon JP, Souhami RL, Stephens RJ, Stewart LA, Tierney JF, Tribodet H, van Meerbeeck J (2010) Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet 375:1267–1277. https://doi.org/10.1016/s0140-6736(10)60059-1
doi: 10.1016/s0140-6736(10)60059-1
pubmed: 20338627
Agrawal AA, Yu L, Smith PG, Buonamici S (2018) Targeting splicing abnormalities in cancer. Curr Opin Genet Dev 48:67–74. https://doi.org/10.1016/j.gde.2017.10.010
doi: 10.1016/j.gde.2017.10.010
pubmed: 29136527
Zhang S, Bao Y, Shen X, Pan Y, Sun Y, Xiao M, Chen K, Wei H, Zuo J, Saffen D, Zong WX, Sun Y, Wang Z, Wang Y (2020) RNA binding motif protein 10 suppresses lung cancer progression by controlling alternative splicing of eukaryotic translation initiation factor 4H. EBioMedicine 61:103067. https://doi.org/10.1016/j.ebiom.2020.103067
doi: 10.1016/j.ebiom.2020.103067
pubmed: 33130397
pmcid: 7585942
de Miguel FJ, Pajares MJ, Martínez-Terroba E, Ajona D, Morales X, Sharma RD, Pardo FJ, Rouzaut A, Rubio A, Montuenga LM, Pio R (2016) A large-scale analysis of alternative splicing reveals a key role of QKI in lung cancer. Mol Oncol 10:1437–1449. https://doi.org/10.1016/j.molonc.2016.08.001
doi: 10.1016/j.molonc.2016.08.001
pubmed: 27555542
pmcid: 5423218